Posts by Mourabit Halima

In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.The study…

As lung cancer diagnosis and treatment enter an era of precision and personalization, Chinese researchers are playing an increasingly pivotal role on the international stage through innovation and collaboration. In this special edition of the Mok Talk interview series, hosted by the talented Professor Yang Xia of The Second Affiliated Hospital of Zhejiang University School of Medicine, we are honored to present a conversation with world-renowned lung cancer expert Professor Tony Mok from The Chinese University of Hong Kong. Joining him are prominent early-career scholars such as Professor Wenhua Liang (The First Affiliated Hospital of Guangzhou Medical University) and Professor Yongchang Zhang (Hunan Cancer Hospital). Together, they discuss academic growth, clinical trial design, and the global impact of Chinese innovations—offering a meaningful intergenerational exchange of ideas.

Trimodality therapy (TMT)is a well-established bladder-sparing strategy for patients with muscle-invasive bladder cancer (MIBC). However, limitations remain for patients intolerant to chemotherapy and in monitoring post-treatment recurrence. Professors Haige Chen and Ruiyun Zhang of Renji Hospital, Shanghai Jiao Tong University School of Medicine, have long focused on MIBC research. This year, nine of their studies were accepted at the EAU Congress. UroStream invited Professors Chen and Zhang to share their insights on emerging approaches, including chemotherapy-free strategies combining the domestic ADC drug RC48 with PD-1 inhibitors, the value of utDNA in non-invasive monitoring, AI-based molecular subtyping, and major takeaways from the congress.

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC) was held with great success. During the conference, the Chinese Society of Clinical Oncology (CSCO) and SGBCC jointly organized the "Voice of China" session, showcasing China's advancements in clinical research, basic science, translational medicine, and radiomics within the breast cancer field, which sparked vibrant discussions among global experts. “Oncology Frontier” invited the co-chairs of this session—Prof. Zefei Jiang (St.Gallen International Consensus panel Member, CSCO President-Elect, Chinese PLA General Hospital) and Prof. Michael Gnant (SGBCC Conference Chair, Comprehensive Cancer Center, Medical University of Vienna)—to engage in a profound dialogue on the future of Sino-global collaboration.

In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer…